Expertise in
8
conditions

Mehmet S. Dal

Ankara, TR 
Expertise in
8
conditions
Ankara, TR 

Overview

Mehmet Dal practices practicing medicine in Ankara, Turkey.

Mr. Dal is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Splenectomy.

He is actively involved in clinical research, co-authoring 142 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Ankara, Turkey
Other Locations
Diyarbakir, Turkey
Afyonkarahisar, Turkey
Dicle, Turkey
Yenisehir, 21280, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3

142 Total Publications

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 06, 2026

Frequently Asked Questions about Mehmet S. Dal

Is Mehmet S. Dal a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Mehmet S. Dal is classified as an Advanced expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mehmet S. Dal participate in research or clinical trials?

Yes. Mehmet S. Dal has published 142 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Mehmet S. Dal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dal's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 52 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile